1. Introduction
===============

20--30% of adults suffered dizziness in their lifetime \[[@b1-2093-6966-v21-n04-241]\]. As common symptom, there are diverse causes for dizziness. Main causes of dizziness comprise central origin, benign paroxysmal positional vertigo, hyperventilation syndrome, otic diseases (eg. Meniere's disease, vestibular neuritis), cardiovascular diseases, cerebrovascular diseases, medication, aging, etc \[[@b2-2093-6966-v21-n04-241], [@b3-2093-6966-v21-n04-241]\] and their symptoms vary widely such as vertigo, disequilibrium, presyncope, lightheadedness accordingly. Among these, cervicogenic dizziness is dizziness or vertigo deriving from a disturbance of the neck which can be owed to impingement of the vertebral arteries, whiplash, or degenerative disturbances of the cervical spine \[[@b4-2093-6966-v21-n04-241]\]. Evidence on the disease has not been developed much so far and physical therapy is mentioned to be preferred for cervicogenic dizziness in general.

Pharmacopuncture is a treatment that combines acupuncture and herbal medicine. Medicinal fluid including herb extract is inserted, inhaled or embedded into the points where acupuncture needle is usually applied (acupoints, meridian sinews, joints, body cavities, blood vessels, etc) to mediate vital function and treat diseases, based on qi/flavor theory and meridian theories \[[@b5-2093-6966-v21-n04-241]\]. In Korea, 98.6% of inpatients and 77.6% of outpatients in 12 Korean medicine hospitals and clinics received pharmacopuncture treatment \[[@b6-2093-6966-v21-n04-241]\]. In China, pharmacopuncture was studied by the terms of 'acupoint injection' or 'aqua acupuncture'. This method is used in wide spectra of diseases such as musculoskeletal disorders, neurological disorders and disorders of digestive system, circulatory system \[[@b7-2093-6966-v21-n04-241]\].

Administration route of pharmacopuncture includes injecting herb extract into acupoints, intravenously injecting herb extracts, injecting chemical compounds into acupoints, or needle-embedding. These routes and solution can be differed in accordance with symptoms or progress of diseases. Acupoints on different body regions were also applied to regulate targeted diseases. The medicinal material can be absorbed by human body rapidly and many resources can be used as component of pharmacopuncture. As dizziness has chronic progress and frequent relapse, pharmacopuncture can be used as new complementary tactic due to these features.

The studies on pharmacopuncture treatment for dizziness included diverse types of dizziness such as inner ear vertigo such as Meniere's disease \[[@b8-2093-6966-v21-n04-241]--[@b10-2093-6966-v21-n04-241]\], vertebral arteriosclerosis \[[@b8-2093-6966-v21-n04-241]\], hypertension \[[@b8-2093-6966-v21-n04-241], [@b9-2093-6966-v21-n04-241]\], vertebrobasilar arterial disease \[[@b8-2093-6966-v21-n04-241], [@b9-2093-6966-v21-n04-241]\], and anemia \[[@b8-2093-6966-v21-n04-241]\]. Interestingly, there were overwhelming number of observational studies and randomized controlled trials \[[@b11-2093-6966-v21-n04-241]--[@b37-2093-6966-v21-n04-241]\] regarding the efficacy of pharmacopuncture for cervicogenic dizziness compared with those for dizziness with other origin, considering its portion which accounts for 7.5% among diverse causes of dizziness \[[@b38-2093-6966-v21-n04-241]\]. There were a number of studies about pharmacopuncture on dizziness, especially cervicogenic dizziness, but overall review on specific treatment forms and methods were not discussed so far. In this regard, this study aimed to review previous researches on cervicogenic dizziness treatment with various forms of pharmacopuncture.

2. Methods
==========

This article aimed to provide narrative review of pharmacopuncture treatment on dizziness as therapeutic option. To achieve this, the authors searched published literature comprehensively. Literature which was published by August 2016 was searched on Pubmed, RISS (<http://www.riss.kr/>), Korean Traditional Knowledge Portal (<http://www.koreantk.com>), Oriental Medicine Advanced Searching Integrated System (OASIS), (<http://oasis.kiom.re.kr/>) and China National Knowledge Infrastructure (CNKI) ([www.cnki.net](www.cnki.net)). Eligible studies were randomized controlled trials that assessed the efficacy of pharmacopuncture on cervicogenic dizziness. Studies were excluded when the study did not include a control group or randomization was not performed. The eligible studies included the method of either injecting herb extract in acupoints and vein or injecting conventional medicine in acupoints, but catgut embedding method and needle embedding method were excluded. Combination of pharmacopuncture with other interventions were basically included but we excluded the cases which were difficult to discriminate the efficacy of pharmacopuncture from the other.

The authors reviewed the titles, abstracts, and article and irrelevant studies were excluded. After the authors read the full article of eligible studies, they summarized and discussed points which deserves consideration in pharmacopuncture treatment for cervicogenic dizziness.

3. Results and Discussion
=========================

Twenty seven studies were included and the number of participants was 2,709 ([Figure 1](#f1-2093-6966-v21-n04-241){ref-type="fig"}). The included studies were all conducted in China. The solution, selected acupoints, and administration method were diverse and the details were summarized as below ([Table 1](#t1-2093-6966-v21-n04-241){ref-type="table"}).

3.1. Types of pharmacopuncture solution used in cervicogenic dizziness
----------------------------------------------------------------------

Single compound derived from medicinal plants or the extract of herbs were commonly used. Salvia miltiorrhiza was most frequently used either by mixture with Dalbergia odorifera (also known as compound Salvia miltiorrhiza injection) \[[@b13-2093-6966-v21-n04-241]--[@b15-2093-6966-v21-n04-241], [@b17-2093-6966-v21-n04-241], [@b21-2093-6966-v21-n04-241]--[@b24-2093-6966-v21-n04-241], [@b26-2093-6966-v21-n04-241], [@b30-2093-6966-v21-n04-241]\] or Carthamus tinctorius \[[@b12-2093-6966-v21-n04-241]\] or Salvia miltiorrhiza alone \[[@b18-2093-6966-v21-n04-241], [@b29-2093-6966-v21-n04-241]\]. Angelica gigas extract \[[@b11-2093-6966-v21-n04-241], [@b15-2093-6966-v21-n04-241], [@b24-2093-6966-v21-n04-241]\], Gastrodin (a compound in Gastrodia elata) \[[@b18-2093-6966-v21-n04-241], [@b25-2093-6966-v21-n04-241], [@b27-2093-6966-v21-n04-241]\] and Panax notoginseng saponins (also known as Xuesaitong) \[[@b15-2093-6966-v21-n04-241], [@b28-2093-6966-v21-n04-241], [@b29-2093-6966-v21-n04-241]\] were also studied in clinical trials. Angelica gigas extract was also used in combination with Ligusticum striatum extract and Carthamus tinctorius extract (also known as compound Angelica injection) \[[@b21-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\] or only with Carthamus tinctorius \[[@b29-2093-6966-v21-n04-241]\]. Besides, the effect of injecting Anisodamine (a compound of Anisodus tanguticus) \[[@b12-2093-6966-v21-n04-241], [@b17-2093-6966-v21-n04-241]\], Ligustrazine (a compound of Ligusticum striatum) \[[@b13-2093-6966-v21-n04-241], [@b34-2093-6966-v21-n04-241]--[@b36-2093-6966-v21-n04-241]\], Carthamus tinctorius \[[@b16-2093-6966-v21-n04-241]\], Scopolamine (alkaloid component of Semen Hyoscyami) \[[@b33-2093-6966-v21-n04-241]\], Ginkgo biloba \[[@b31-2093-6966-v21-n04-241]\] and Puerarin (a compound of Pueraria lobate) \[[@b32-2093-6966-v21-n04-241]\] was also studied for cervicogenic dizziness. Injecting compound Angelica injection in Ashi points, cervical paravertebral points, ST36, GB20 and BL23 combined with body acupuncture significantly improved symptom compared with body acupuncture alone (97.5% versus 80.0%, P \< 0.05) \[[@b37-2093-6966-v21-n04-241]\].

Pharmacopuncture solution was usually applied soley to human body. In some studies they were used as mixture with other conventional medicine like lidocaine \[[@b15-2093-6966-v21-n04-241]--[@b17-2093-6966-v21-n04-241], [@b24-2093-6966-v21-n04-241]\], Vitamin B12 \[[@b15-2093-6966-v21-n04-241], [@b16-2093-6966-v21-n04-241], [@b24-2093-6966-v21-n04-241]\], betahistine \[[@b13-2093-6966-v21-n04-241]\]. Injecting combination of Angelica gigas extract, compound Salvia miltiorrhiza, Panax notoginseng saponins, lidocaine, and Vitamin B12inGB20, BL10 and GV16 had significantly better efficacy compared with body acupuncture group (symptom improvement 96.7% versus 80.0%, X2 = 3.96, P \< 0.05) \[[@b15-2093-6966-v21-n04-241]\] Statistical difference was found in injecting Carthamus tinctorius, lidocaine, Vitamin B12 in GV20, GB20, cervical paravertebral points compared with cervical traction and iontophoresis with herbal Angelica sinensis, Ligusticum striatum, Corydalis yanhusuo, Clematis chinensis, Gentianae Macrophylla, Phryma leptostachya, etc) (symptom improvement 96.4% versus 75.0%, X2 = 4.90, P \< 0.05) \[[@b16-2093-6966-v21-n04-241]\]. Compound Salvia miltiorrhiza injected in GB20 effectively improved symptom compared with acupuncture alone in cervical paravertebral points (95% versus 81%, P \< 0.05) \[[@b14-2093-6966-v21-n04-241]\]. When pharmacopuncture solution was infused intravenously, it was diluted to intravenous fluids such as normal saline or 5% dextrose in water \[[@b12-2093-6966-v21-n04-241], [@b13-2093-6966-v21-n04-241], [@b17-2093-6966-v21-n04-241]--[@b19-2093-6966-v21-n04-241], [@b21-2093-6966-v21-n04-241]--[@b25-2093-6966-v21-n04-241], [@b27-2093-6966-v21-n04-241], [@b28-2093-6966-v21-n04-241], [@b30-2093-6966-v21-n04-241]--[@b32-2093-6966-v21-n04-241]\].

Conventional medicine (lidocaine \[[@b20-2093-6966-v21-n04-241]\], Vitamin B12 \[[@b20-2093-6966-v21-n04-241]\], Vitamin B1 \[[@b20-2093-6966-v21-n04-241]\], Vitamin B6 \[[@b33-2093-6966-v21-n04-241]\], dexamethasone \[[@b20-2093-6966-v21-n04-241]\]) was often injected in acupoints. Injecting lidocaine, Vitamin B12, VitaminB1, dexamethasone in ST10, GB20, GV14, and cervical paravertebral points was superior to oral administration of aspirin and intravenous administration of panax notoginseng saponins and citicoline in the change of blood flow velocity monitored by transcranial Doppler ultrasonography (P \< 0.05) \[[@b20-2093-6966-v21-n04-241]\].

3.2. Importance of adapting acupoints in pharmacopuncture
---------------------------------------------------------

Researches studied efficacy of pharmacopuncture applied in acupoints. \[[@b11-2093-6966-v21-n04-241]--[@b26-2093-6966-v21-n04-241], [@b29-2093-6966-v21-n04-241], [@b33-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\]. Some studies especially revealed that injecting solution in acupoints is more effective than injecting the identical solution intravenously. Applying Salvia miltiorrhiza in GB20 and BL10 showed better efficacy than injecting Salvia miltiorrhiza intravenously (symptom improvement 95.0% versus 66.7%, X2 = 9.855, P \< 0.01) \[[@b19-2093-6966-v21-n04-241]\]. While control group adapted intravenous injection of compound Salvia miltiorrhiza and oral administration of herbal decoction, injecting compound Salvia miltiorrhiza in GV20, CV04 and Jingyun acupoint (0.8 cun lateral to the space between C5--6 spinous processes) showed significant difference (100.0% versus 86.2, P \< 0.01) and the efficacy was consistent in patients of different syndrome differentiations \[[@b22-2093-6966-v21-n04-241]\]. Injecting compound Salvia miltiorrhiza in GB20 and cervical paravertebral points showed better effiicacy in comparison with intravenously injecting compound Salvia miltiorrhiza and orally taking flunarizine hydrochloride (symptom improvement 97.1% versus 76.5%, X2 = 4.61, P \< 0.05) \[[@b23-2093-6966-v21-n04-241]\]. These findings are well worth considering in terms of the importance of exploiting acupoints in pharmacopuncture.

Many researcher have selected GB20 the most for PA injection point in cervicogenic dizziness \[[@b11-2093-6966-v21-n04-241]--[@b21-2093-6966-v21-n04-241], [@b23-2093-6966-v21-n04-241], [@b24-2093-6966-v21-n04-241], [@b26-2093-6966-v21-n04-241], [@b29-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\]. GV20 was also popular acupoint for cervicogenic dizziness \[[@b8-2093-6966-v21-n04-241], [@b16-2093-6966-v21-n04-241], [@b22-2093-6966-v21-n04-241]\]. GB20 \[[@b8-2093-6966-v21-n04-241], [@b9-2093-6966-v21-n04-241], [@b39-2093-6966-v21-n04-241]\] and GV20 \[[@b8-2093-6966-v21-n04-241]--[@b10-2093-6966-v21-n04-241]\] were similarly frequently selected in phamacopuncture treatment for dizziness of other causes. As for cervicogenic dizziness, the acupoints located on occipital region such as cervical paravertebral points \[[@b16-2093-6966-v21-n04-241], [@b20-2093-6966-v21-n04-241], [@b21-2093-6966-v21-n04-241], [@b23-2093-6966-v21-n04-241]--[@b26-2093-6966-v21-n04-241], [@b33-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\], BL10 \[[@b15-2093-6966-v21-n04-241], [@b19-2093-6966-v21-n04-241], [@b26-2093-6966-v21-n04-241]\] and GV16 \[[@b21-2093-6966-v21-n04-241]\] which are adjacent to GB20, were mainly used in cervicogenic dizziness. Among distal acupoints, ST36 was mostly used \[[@b8-2093-6966-v21-n04-241], [@b11-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\].

3.3. Pharmacopuncture as complement to conventional treatment for cervicogenic dizziness
----------------------------------------------------------------------------------------

Pharmacopuncture yielded synergetic effect when it is used with conventional treatment for cervicogenic dizziness. Injecting Anisodamine in GB20 yielded complementary effect when it was added to cervical traction, intravenous injection of Salvia miltiorrhiza and Carthamus tinctorius and oral administration of herbal medicine (98.3% versus 86.2%, P \< 0.05) \[[@b12-2093-6966-v21-n04-241]\]. Adding compound Salvia miltiorrhiza in GB20 and BL10 enhanced the efficacy from the control group which simply received physical therapy, cervical traction, and manipulation (symptom improvement 94.1% versus 76.4%, X2 = 4.86, P \< 0.05) \[[@b26-2093-6966-v21-n04-241]\]. Injecting scopolamine and vitamin B6 in cervical paravertebral points yielded better efficacy compared with the control which received usual treatment comprising conventional medicine, herbal medicine, tuina, cervical traction and physiotherapy (symptom improvement 100% versus 89.2%, U = 2.0143, P \< 0. 05) \[[@b33-2093-6966-v21-n04-241]\].

3.4. Interaction with body acupuncture
--------------------------------------

Some studies have shown that combining body acupuncture with pharmacopuncture resulted in better efficacy on cervicogenic dizziness than treating with body acupuncture alone. Intravenous injection of Gastrodin with body acupuncture group was better than either body acupuncture group or Gastrodin injection group (symptom improvement 94.7% versus 86.8% versus 57.9%) and it showed significant difference compared with Gastrodin injection group (P \< 0.05) but not with body acupuncture group (P \> 0.05) \[[@b27-2093-6966-v21-n04-241]\]. Injecting compound Angelica in acupoints combined with body acupuncture showed better efficacy than body acupuncture alone (symptom improvement 97.5% versus 80.0%, P \< 0.05) \[[@b37-2093-6966-v21-n04-241]\].

On the other hand, several studies reported that body acupuncture exceeded the efficacy of intravenous injection of pharmacopuncture. Body acupuncture showed better efficacy than daily intravenous injection of Panax notoginseng saponins (symptom improvement 91.4% versus 71.4%, P \< 0.05) \[[@b28-2093-6966-v21-n04-241]\]. Penetrating across both GB20 with dry needle had better efficacy than intravenous administration of compound Salvia Miltiorrhiza (100.0% versus 46.7%, P \< 0.01) \[[@b30-2093-6966-v21-n04-241]\]. Applying acupuncture on GB20, GV20, PC06, cervical paravertebral points and additional acupoints according to syndrome differentiation was more effective than intravenous injection of Ginkgo biloba (symptom improvement 93.3% versus 68.3%, P \< 0.05) \[[@b31-2093-6966-v21-n04-241]\]. Applying acupuncture on GB20, GV21, GB21, GV14, GV13, LR03 and cervical paravertebral points was significantly better than injecting Puerarin \[[@b32-2093-6966-v21-n04-241]\]. Treatment group received head acupuncture on GB20, BL10, GB12, GV14 with injecting Panax notoginseng saponins, Angelica gigas extract and Carthamus tinctorius extract in GB20 while the control group had intravenous injection of Salvia miltiorrhiza extract and oral administration of Nimodipine. Both groups had significant change after the treatment and the former group have significant difference compared with the latter group \[[@b29-2093-6966-v21-n04-241]\].

4. Conclusion
=============

Dizziness is a very common but debilitating symptom that often impedes patients from maintaining everyday lives. For this reason, new intervention for dizziness is important and its adjunctive use with other current treatments would improve the severity and duration of the symptom. Pharmacopuncture would make up for it and a great number of pharmacopuncture studies for cervicogenic dizziness indicates its possibility. Its vast studies might be partially related to traditional use of acupuncture on cerebrovascular diseases \[[@b40-2093-6966-v21-n04-241]\].

Throughout previous trials, diverse kinds of injecting solution were used. The same solutions were both injected on acupoints \[[@b11-2093-6966-v21-n04-241]--[@b24-2093-6966-v21-n04-241], [@b26-2093-6966-v21-n04-241], [@b29-2093-6966-v21-n04-241], [@b30-2093-6966-v21-n04-241], [@b33-2093-6966-v21-n04-241], [@b37-2093-6966-v21-n04-241]\] or injected intravenously \[[@b12-2093-6966-v21-n04-241], [@b13-2093-6966-v21-n04-241], [@b17-2093-6966-v21-n04-241]--[@b24-2093-6966-v21-n04-241], [@b27-2093-6966-v21-n04-241]--[@b31-2093-6966-v21-n04-241], [@b35-2093-6966-v21-n04-241]\]. These issues leave the necessity to establish the criteria for selecting the injection solution and their usage according to certain symptoms or features of dizziness. Several studies reported the efficacy of needling in acupoints over intravenous injection of pharmacopuncture and acupoints on occipital region were distinctively used for cervicogenic dizziness. These results remind us the importance of adoption of acupoints and their selection. Principles or schematized plan of pharmacopuncture treatment depending on the type of dizziness should be investigated further.
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###### 

Characteristics of RCTs of pharmacopuncture for cervicogenic dizziness

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author; pub. year                                                        No. of participants; Age[\*](#tfn1-2093-6966-v21-n04-241){ref-type="table-fn"}   Duration of disease[\*](#tfn1-2093-6966-v21-n04-241){ref-type="table-fn"}   Intervention type                                                                                                                 Injection route and acupoints                                                             Treatment period   Type of control group                                           Outcome measure                                                            Results                                                                  Adverse events
  ------------------------------------------------------------------------------ -------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------
  Cao, 2013 \[[@b11-2093-6966-v21-n04-241]\]                                     120; 18 \~ 70                                                                    1d \~ 10y                                                                   Angelica gigas extract, IA, qd                                                                                                    GB20, ST36, holographic acupoints on second metacarpal bones                              11d \~ 17d         • Tuina, qd\                                                    Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Herbal medicine, po, tid                                                                                                                                                                                          

  Chang, 2015 \[[@b12-2093-6966-v21-n04-241]\]                                   116; 43.0                                                                        10.1m                                                                       • Anisodamine\                                                                                                                    Anisodamine: GB20 Salvia miltiorrhiza, Carthamus tinctorius: IV                           10d                • Cervical traction, qid\                                       Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • Cervical traction, qid\                                                                                                                                                                                                                      • Salvia miltiorrhiza, Carthamus tinctorius, IV\                                                                                                                                                                    
                                                                                                                                                                                                                                              • Salvia miltiorrhiza, Carthamus tinctorius, IV\                                                                                                                                                                                               • Herbal medicine, po                                                                                                                                                                                               
                                                                                                                                                                                                                                              • Herbal medicine, po                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Huo, 2010 \[[@b13-2093-6966-v21-n04-241]\]                                     80; \> 40                                                                        NR                                                                          • Ligustrazine, IA, qd\                                                                                                           Ligustrazine: GB20 Salvia miltiorrhiza, Dalbergia odorifera: IV                           22d                Salvia miltiorrhiza, Dalbergia odorifera, betahistine, IV, qd   Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • Salvia miltiorrhiza, Dalbergia odorifera, betahistine, IV, qd                                                                                                                                                                                                                                                                                                                                                                                                    

  Li, 2006 \[[@b14-2093-6966-v21-n04-241]\]                                      74; 32 \~ 69                                                                     1y \~ 21y                                                                   Salvia miltiorrhiza, Dalbergia odorifera, IA qod                                                                                  GB20                                                                                      24d                AT, qd                                                          Symptom improvement                                                        T \> C, P \< 0.05                                                        NR

  Liu, 2001 \[[@b15-2093-6966-v21-n04-241]\]                                     300; 27 \~ 58                                                                    1m \~ 12y                                                                   Salvia miltiorrhiza, Dalbergia odorifera, Angelica gigas extract, Panax notoginseng saponins, lidocaine, vitamin B~12~, IA, q3d   GB20, BL10, GV16                                                                          15d                AT, GV16                                                        Symptom improvement                                                        T \> C, P \< 0.05                                                        NR

  Wang, 2009 \[[@b16-2093-6966-v21-n04-241]\]                                    48; 18 \~ 77                                                                     20d \~ 6y                                                                   • Carthamus tinctorius, lidocaine, vitamin B~12~,tid                                                                              GV20, GB20, cervical paravertebral points                                                 12d                • Cervical traction, bid\                                       Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Iontophoresis with herbal                                                                                                                                                                                         

  Cao, 2005 \[[@b17-2093-6966-v21-n04-241]\]                                     35; 47.9                                                                         1d \~ 15y                                                                   Anisodamine, lidocaine, IA, qd                                                                                                    GB20                                                                                      7d                 Salvia miltiorrhiza, Dalbergia odorifera, IV, qd                \(1\) Symptom improvement\                                                 \(1\) T \> C, P \< 0.05\                                                 NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (2) Relapse rate for the first year                                        (2) T \> C, P \< 0.05                                                    

  Weng, 2006 \[[@b18-2093-6966-v21-n04-241]\]                                    112; \> 45                                                                       3m\~10y                                                                     • Gastrodin, IA, q3d\                                                                                                             GB20                                                                                      9d                 Salvia miltiorrhiza, IV, qd                                     \(1\) Symptom improvement\                                                 \(1\) T \> C, P \< 0.05\                                                 NR
                                                                                                                                                                                                                                              • Flunarizine hydrochloride, po, qd                                                                                                                                                                                                                                                                            (2) Change of TCD flow velocity                                            (2) Vd: VA \[left\]: P \< 0.05, VA \[right\]: P \> 0.05, BA: P \< 0.01   

  Zou, 2007 \[[@b19-2093-6966-v21-n04-241]\]                                     73; 35 **\~ 70**                                                                 1m\~6y                                                                      Salvia miltiorrhiza, qod                                                                                                          GB20, BL10                                                                                20d                Salvia medicine, IV                                             Symptom improvement                                                        **T \> C, P \< 0**.01 05                                                 **NR**

  Ju, 2011 \[[@b20-2093-6966-v21-n04-241]\]                                      80; 57.5                                                                         11.7d                                                                       Lidocaine, vitamin B~12,~vitaminB~1,~dexamethaso ne,IA,qod                                                                        ST10, GB20, GV14, and cervical paravertebral point                                        10d                • Aspirin, po\                                                  Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Panax notoginseng saponins, citicoline, IV, qd                                                                                                                                                                    

  Yang, \[[@b12-2093-6966-v21-n04-241]\] 2010 \[[@b21-2093-6966-v21-n04-241]\]   78; NR                                                                           NR                                                                          Angelica gigas extract, Ligusticum striatum extract and Carthamus tinctorius extract, IA, qd                                      GB20, cervical paravertebral points, GV16                                                 14d                Salvia miltiorrhiza, Dalbergia odorifera, IV, qd                Symptom improvement and change of TCD flow velocity                        T \> C, P \< 0.05                                                        NR

  Sun, 2001 \[[@b22-2093-6966-v21-n04-241]\]                                     242; 26 \~ 77                                                                    1d \~ 14y                                                                   Salvia miltiorrhiza, Dalbergia odorifera, IA qd                                                                                   GV20, CV04, Jingyun acupoint, additional acupoints according to pattern differentiation   22d                • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd\             Symptom improvement                                                        T \> C, P \< 0.01                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Herbal medicine, po                                                                                                                                                                                               

  Yang, 2006 \[[@b23-2093-6966-v21-n04-241]\]                                    68; 29 \~ 72                                                                     12d \~ 7m                                                                   Salvia miltiorrhiza, Dalbergia odorifera, IA, qod                                                                                 GB20, cervical paravertebral points                                                       27d                • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd\             Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Flunarizine hydrochloride, po, qd                                                                                                                                                                                 

  Wang, 2003 \[[@b24-2093-6966-v21-n04-241]\]                                    48; 28 \~ 67                                                                     3d \~ 5y                                                                    Salvia miltiorrhiza, Dalbergia odorifera, Angelica gigas extract, lidocaine, vitamin B~12~, IA, qd                                GB20, cervical paravertebral points                                                       25d                • Salvia miltiorrhiza, Dalbergia odorifera, IV, qd\             Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             • Flunarizine hydrochloride, po, qd                                                                                                                                                                                 

  Tang, 2011 \[[@b25-2093-6966-v21-n04-241]\]                                    60; 43 \~ 69                                                                     NR                                                                          • Gastrodin\                                                                                                                      cervical paravertebral points                                                             10d                Gastrodin, IV, qd                                               Scoring for dizziness                                                      T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • AT, qd                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Wang, 2008 \[[@b26-2093-6966-v21-n04-241]\]                                    68; 42.0                                                                         3.2y                                                                        • Salvia miltiorrhiza, Dalbergia odorifera, IA, qd\                                                                               GB20, BL10, cervical paravertebral points                                                 22d                • Physical therapy, cervical traction, manipulation, qd         Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • Physical therapy, cervical traction, manipulation, qd                                                                                                                                                                                                                                                                                                                                                                                                            

  Xiao, 2016 \[[@b27-2093-6966-v21-n04-241]\]                                    114; 49.8                                                                        2m \~ 14y                                                                   • Gastrodin, IV, qd\                                                                                                              IV                                                                                        20d                • Group1: AT, qd\                                               Scoring for symptoms and function rehabilitation of cervical vertigo       • Group1: T \> C, P \> 0.05\                                             NR
                                                                                                                                                                                                                                              • AT, qd                                                                                                                                                                                                                                       • Group2: Gastrodin, IV, qd                                                                                                                • Group2: T \> C, P \< 0.05                                              

  Tan, 2013 \[[@b28-2093-6966-v21-n04-241]\]                                     70; 43.2                                                                         5d \~ 8y                                                                    Panax notoginseng saponins, IV, qd                                                                                                IV                                                                                        14d                AT, qd                                                          Symptom improvement                                                        T \< C, P \< 0.05                                                        NR

  Long, 2004 \[[@b29-2093-6966-v21-n04-241]\]                                    92; 36 \~ 70                                                                     2m \~ 10y                                                                   • Panax notoginseng saponins, Angelica gigas extract, Carthamus tinctorius extract, IA,qod\                                       GB20                                                                                      30d                • Salvia miltiorrhiza, IV, qd\                                  \(1\) Symptom improvement\                                                 \(1\) T \> C, P \< 0.05\                                                 NR
                                                                                                                                                                                                                                              • AT, qd                                                                                                                                                                                                                                       • Nimodipine, tid                                               (2) Scoring for symptoms and function rehabilitation of cervical vertigo   (2) T \> C, P \< 0.01                                                    

  Zhang, 2011 \[[@b30-2093-6966-v21-n04-241]\]                                   75; 30 \~ 78                                                                     2h \~ 20y                                                                   Salvia miltiorrhiza, Dalbergia odorifera, IV, qd                                                                                  IV                                                                                        10d                AT, qd\~bid                                                     Symptom improvement                                                        T \< C, P \< 0.01                                                        NR

  Zhu, 2012 \[[@b31-2093-6966-v21-n04-241]\]                                     120; 37 \~ 74                                                                    NR                                                                          Ginkgo biloba, IV, qd                                                                                                             IV                                                                                        28d                AT, qd                                                          \(1\) Dizziness symptom score\                                             \(1\) T \< C, P \< 0.05\                                                 NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (2) Symptom improvement                                                    (2) T \< C, P \< 0.05                                                    

  Li, 2006 \[[@b32-2093-6966-v21-n04-241]\]                                      108; 50 \~ 75                                                                    6m \~ 12y                                                                   Puerarin, qd                                                                                                                      IV                                                                                        15d                AT, qd                                                          Symptom improvement                                                        P \< 0.01                                                                NR

  Li, 1998 \[[@b33-2093-6966-v21-n04-241]\]                                      140; 38 \~ 67                                                                    12d \~ 5y                                                                   • Scopolamine, vitamin B~6~, IA, qd\                                                                                              cervical paravertebral points                                                             10d                • Herbal medicine\                                              Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • AT, qd                                                                                                                                                                                                                                       • Tuina, cervical traction, physiotherapy                                                                                                                                                                           

  Jin, 2014 \[[@b34-2093-6966-v21-n04-241]\]                                     82; 37 \~ 74                                                                     NR                                                                          • Ligustrazine, IV, qd\                                                                                                           IV                                                                                        14d                • Cinepazide maleate, IV, qd\                                   \(1\) Remission time of dizziness, tinnitus and balance disorder\          \(1\) T \< C, P \< 0.05\                                                 NR
                                                                                                                                                                                                                                              • Symptomatic treatment                                                                                                                                                                                                                        • Symptomatic treatment                                         (2) Symptom improvement and change of TCD flow velocity                    (2) T \< C, P \< 0.05                                                    

  Yi, 2012 \[[@b35-2093-6966-v21-n04-241]\]                                      98; 35 \~ 74                                                                     NR                                                                          Ligustrazine, IV, qd                                                                                                              IV                                                                                        14d                Cinepazide maleate, IV, qd                                      Symptom improvement and change of TCD flow velocity                        T \< C, P \< 0. 05                                                       NR

  He, 2013 \[[@b36-2093-6966-v21-n04-241]\]                                      128; 57 \~ 78                                                                    NR                                                                          Ligustrazine, IV, qd                                                                                                              IV                                                                                        NR                 Cinepazide maleate, IV, qd                                      Symptom improvement                                                        T \< C, P \< 0.05                                                        NR

  Yang, 2015 \[[@b37-2093-6966-v21-n04-241]\]                                    80; 25 \~ 72                                                                     5m \~ 13y                                                                   • Angelica gigas extract, Ligusticum striatum extract and Carthamus tinctorius extract, IA, qod\                                  Ashi points, cervical paravertebral points, ST36, GB20 and BL23                           21d                AT, qod                                                         Symptom improvement                                                        T \> C, P \< 0.05                                                        NR
                                                                                                                                                                                                                                              • AT, qod                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The values are presented as range or average.

Abbreviations: publication, pub.; number, no.; control group, C; Treatment group, T; day, d; month, m; year, y;everyday, qd; every other day, qod; every third day, q3d; twice a day, bid; three times a day, tid; four times a day, qid; acupuncture, AT; systolic velocity, Vs; diastolic velocity, Vd; vertebral artery, VA; basilar artery, BA; intra-acupoint, IA; intravenously, IV; not reported, NR;
